Why Is Tempus AI Stock Surging On Thursday?
Summary
Tempus AI stock rose after the company expanded its AI-enabled Next platform with new clinical indications. The update adds coverage across six cancer scenarios and introduces new intelligence features for precision medicine teams. Tempus says the platform can analyze unstructured EHR data to find patients who are missing guideline-directed testing and quantify intervention opportunities. The company will also present ASCO data showing improved biomarker testing rates in early-stage non-small cell lung cancer. This release strengthens Tempus’ position with health system partners that want better patient insight and care-gap detection.
Classifications
industries
HealthTech
applications
AI & Machine learning
AskAI Classifications
Labels
Healthcare Software
Precision Medicine
AI-enabled Software
Linked Companies
Tempus
$1M to $5M